Home/Biosimilar Atlas/Companies/Biogenomics

Biogenomics

Biosimilar developer, India. 1 development product across 1 molecule: insulin aspart.

First approval in the Atlas: Oct 2021, Biogenomics (INN only), insulin aspart (CDSCO)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved1
EDEproducts registered0
Connections
1molecule1product1 of 7markets0candidates in trials3companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Insulin aspartBiogenomics insulin aspart·····Oct 2021·1/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Biogenomics, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Biocon BiologicsOne shared molecule: insulin aspart9 molecules in its portfolioGan & Lee PharmaceuticalsOne shared molecule: insulin aspart3 molecules in its portfolioSanofiOne shared molecule: insulin aspart3 molecules in its portfolio

Chronology

Compare Biogenomics with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.